[Congestive cardiomyopathy after doxorubicin (adriamycin)author's transl)].
Doxorubicin at a dose of 470 mg/m2 body surface, was administered to a 15-year-old boy with metastasising osteosarcoma. The cumulative dose caused severe "secondary congestive cardiomyopathy", which ended fatally, although the cumulative dose was below the recommended limit of 550 mg/m2. No other treatment for the tumour had been given. Postmortem examination revealed obliterative lesions in the intramural coronary vessels and electron-microscopy showed all the features of a cardiomyopathy at cellular level.
D000293:Adolescent; D001344:Autopsy; D001859:Bone Neoplasms / Q000188:drug therapy; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy
D004317:Doxorubicin
Sekundre kongestive Kardiomyopathie nach Adriamycin.